Literature DB >> 1185813

Acetic acid, a potent stimulator of mouse epidermal macromolecular synthesis and hyperplasia but with weak tumor-promoting ability.

T J Slaga, G T Bowden, R K Boutwell.   

Abstract

The effects of a single application of various dose levels of acetic acid or the weak tumor promoter, phorbol-12,13-ditetradecanoate, on the incorporation of tritiated thymidine (3H-TDR), 3H-cytidine, and 3H-leucine into DNA, RNA, and protein of mouse epidermis, respectively, were determined and compared with histologic changes in the skin. Treatment with either 500 or 833 mumoles acetic acid induced a sequential and sustained stimulation of RNA, protein, and DNA synthesis, which was followed by extensive epidermal hyperplasia similar to that reported for the strong promoter and irritant, 12-O-tetradecanoyl-phorbol-13-acetate. A dose-response relationship between the amount of acetic acid and the rate of DNA synthesis was found between the dose levels of 33 to 833 mumoles of acetic acid per application. The latter dose induced the maximum activation of 3H-TDR into DNA at 723% of control at 2 days, whereas 33 mumoles stimulated DNA synthesis earlier and peaked at 210% of control at 3 hours. Phorbol-12,13-ditetradecanoate also stimulated macromolecular synthesis in a similar sequence, though to a lesser degree. No observable inflammation and only a slight hyperplastic response were noted with phorbol-12,13-ditetradecanoate. Weekly applications of 667 mumoles of acetic acid produced a maximal tumor response of 0.73 papilloma/mouse after 32 weeks of promotion. However, a weekly dose of 677 mumoles of acetic acid was essentially inactive when given in two divided doses. When croton oil was administered twice weekly at a 0.25%-dose level, 10.2 papillomas/mouse were induced after 32 weeks of promotion. The results showed that the previously considered nonpromoting inflammatory agent, acetic acid, must be a weak promoter. However, there was no correlation between stimulated macromolecular synthesis or hyperplasia and tumor promotion when phorbol esters were compared with acetic acid.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1185813     DOI: 10.1093/jnci/55.4.983

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  8 in total

1.  Acetic acid pretreatment of initiated epidermis inhibits tumour promotion by a phorbol ester.

Authors:  A W Murray
Journal:  Experientia       Date:  1978-11-15

2.  Comparison of differentiation patterns in 12-O-tetradecanoylphorbol-13-acetate-treated epidermis and fetal epidermis.

Authors:  M Chiba; C M Taylor; A J Klein-Szanto
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

3.  Skin tumor promotion by phorbol esters is a two-stage process.

Authors:  G Fürstenberger; D L Berry; B Sorg; F Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

4.  Studies on the mechanism of skin tumor promotion: evidence for several stages in promotion.

Authors:  T J Slaga; S M Fischer; K Nelson; G L Gleason
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

5.  Effects of phorbol myristate acetate, phorbol dibutyrate, ethanol, dimethylsulfoxide, phenol, and seven metabolites of phenol on metabolic cooperation between Chinese hamster V79 lung fibroblasts.

Authors:  A R Malcolm; L J Mills; E J McKenna
Journal:  Cell Biol Toxicol       Date:  1985-10       Impact factor: 6.691

6.  Report of the Federal Panel on Formaldehyde.

Authors: 
Journal:  Environ Health Perspect       Date:  1982-02       Impact factor: 9.031

Review 7.  Overview of tumor promotion in animals.

Authors:  T J Slaga
Journal:  Environ Health Perspect       Date:  1983-04       Impact factor: 9.031

Review 8.  Defective responses of transformed keratinocytes to terminal differentiation stimuli. Their role in epidermal tumour promotion by phorbol esters and by deep skin wounding.

Authors:  E K Parkinson
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.